Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
12 December 2017 - 8:05AM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Scott
Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley
previously served as the company’s Vice President of Medical
Affairs, and in his new role, he assumes responsibility for all
medical matters at Flexion, including Medical Affairs, Clinical
Research and Clinical Operations.
“Scott has demonstrated a singular combination of rigor and
creativity with respect to clinical trial design, clinical data
analysis and the consideration of pipeline candidates, and he melds
those skills with an innate ability to communicate ideas and data
with passion and clarity,” said Michael Clayman, M.D., President
and Chief Executive Officer of Flexion. “Scott’s promotion reflects
his impressive capabilities and accomplishments, and we look
forward to his continued success in his expanded role at this
critical juncture in the company’s evolution.”
Prior to joining Flexion in May of 2016, Dr. Kelley served as
Vice President, Global Medical Affairs, at Sanofi, where he oversaw
global data generation, data dissemination and key opinion leader
engagement for the Biosurgery portfolio including Synvisc®.
Previously, he led medical affairs functions at Covidien
Respiratory & Monitoring Solutions and Aspect Medical Systems.
He obtained his bachelor’s and master’s degrees from Stanford
University and earned his medical degree at the University of
California, San Francisco (UCSF). He completed his residency and
fellowship in anesthesiology at UCSF and obtained board
certifications in anesthesiology and pain management.
Dr. Kelley succeeds Yamo Deniz, M.D., who has left the company
to pursue other opportunities.
About Flexion TherapeuticsFlexion Therapeutics
(Nasdaq:FLXN) is a specialty pharmaceutical company focused on the
development and commercialization of novel, local therapies for the
treatment of patients with musculoskeletal conditions, beginning
with osteoarthritis, a type of degenerative arthritis. The
company's core values are focus, ingenuity, tenacity, transparency
and fun. Flexion was named one of the Boston Business Journal's
2017 Best Places to Work and one of the Top Places to Work in
Massachusetts by The Boston Globe.
Forward-Looking StatementsStatements in this
press release regarding matters that are not historical facts,
including, but not limited to, statements relating to the future
expected benefits of Flexion’s appointment of Dr. Kelley to Chief
Medical Officer, are forward-looking statements. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those expressed or implied
by such statements. These risks and uncertainties include, without
limitation, whether we are able to retain key employees including
Dr. Kelley; our ability to meet our goals; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission (SEC), including under the heading "Risk
Factors" in our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017 filed with the SEC on November 6, 2017. The
forward-looking statements in this press release speak only as of
the date of this press release, and we undertake no obligation to
update or revise any of the statements. We caution investors not to
place considerable reliance on the forward-looking statements
contained in this press release.
Contacts:
Scott
Young
Sr. Director, Corporate Communications & Investor
RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2024 to May 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From May 2023 to May 2024